Article

Interprofessional Education Session Boosts Arthritis Self-Efficacy

A 1-day inflammatory arthritis education session, delivered by an interprofessional arthritis care team, is feasible and replicable.

A 1-day inflammatory arthritis education session, delivered by an interprofessional arthritis care team, is feasible and replicable. Participation improves arthritis self-efficacy and other related outcomes in persons with arthritis.

Kennedy and colleagues conducted a pilot study to evaluate the Prescription for Education, or RxEd, program. A patient-based needs assessment and ongoing patient feedback before recruitment guided program development. Patients were eligible if they had a diagnosis of rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, inflammatory bowel disease–related arthritis, or gout. A quasiexperimental design with waitlisted control crossover was used for evaluation. Self-report questionnaires served as the data collection tool. Generalized estimating equations (GEE) analysis was used to create a statistical model for the repeated measures.

For the primary outcome, the I group (immediate RxEd) showed improved arthritis self-efficacy after the intervention and sustained the effect at 1 year. The C group (RxEd 6 months later) showed no effect until crossover (immediate improvement, which diminished over 6 months). GEE analysis showed significant main effect, before to after the program, in both groups for the primary outcome and most secondary outcomes.

The authors noted that their results warrant further evaluation using more rigorous methods.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.